Stock A225430 KMPHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights KMPHARMACEUTICAL Co.,Ltd.

Equities

A225430

KR7225430008

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 07/06/2024 am IST 		5-day change 1st Jan Change
828 KRW +0.24% Intraday chart for KMPHARMACEUTICAL Co.,Ltd. +3.50% -15.34%
2018 Km Pharmaceutical Co., Ltd. completed the acquisition of IBKS No.3 Special Purpose Acquisition Company in a reverse merger transaction. CI
2018 IBKS No.3 Special Purpose Acquisition Company‘s Equity Buyback announced on March 1, 2018, has expired. CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Km Pharmaceutical Co., Ltd. completed the acquisition of IBKS No.3 Special Purpose Acquisition Company in a reverse merger transaction.
CI
IBKS No.3 Special Purpose Acquisition Company‘s Equity Buyback announced on March 1, 2018, has expired.
CI
Sungkeun Mun acquired 4.9% stake in Km Pharmaceutical Co., Ltd. from K Investment Co., Ltd., Shinhan Investment Corp., KTB Growth Industry Hedge Fund, KTB Mezzanine Private Investment Trust No. 73, and KTB Mezzanine Private Investment Trust No. 74, funds managed by KTB Asset Management Co., Ltd for KRW 2.7 billion.
CI
Km Pharmaceutical Co., Ltd. cancelled the acquisition of 4% in Iconix Co., Ltd. from Wonjung Kim, Hyunsoo Seo, Changhwan Shin, Youngsik Im and Miyoung Jung.
CI
Km Pharmaceutical Co., Ltd. announces an Equity Buyback.
CI
Km Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
Km Pharmaceutical Co., Ltd. entered into an agreement to acquire IBKS No.3 Special Purpose Acquisition Company in a reverse merger transaction.
CI
K Investment Co., Ltd. acquired 1% stake in Km Pharmaceutical Co., Ltd. from Mun, Sung Keun for approximately KRW 500 million.
CI
Juyong Shin acquired 0.18% stake in Km Pharmaceutical Co., Ltd. from Sung Keun Mun for KRW 90.4 million.
CI
Shinhan Investment Corp., KTB Growth Industry Hedge Fund, KTB Mezzanine Private Investment Trust No. 73 and KTB Mezzanine Private Investment Trust No. 74 funds managed by KTB Asset Management Co., Ltd acquired 3.92% in Km Pharmaceutical Co., Ltd. from Mun, Sung Keun for KRW 2 billion.
CI
Km Pharmaceutical Co., Ltd. signed a contract to acquire 4% in Iconix Co., Ltd. from Wonjung Kim, Hyunsoo Seo, Changhwan Shin, Youngsik Im and Miyoung Jung for KRW 4 billion.
CI
ST Capital Co., Ltd and Youngin Seo acquired 0.15% stake in Km Pharmaceutical Co., Ltd from Sunggeun Moon for KRW 75 million.
CI
ST Capital Co., Ltd acquired an additional 0.25% stake in Km Pharmaceutical Co., Ltd from Sunggeun Mun for approximately KRW 130 million.
CI
ST Capital Co., Ltd and Youngin Seo acquired 0.74% stake in Km Pharmaceutical Co., Ltd from Sunggeun Moon for approximately KRW 380 million.
CI
Sunggeun Moon sold 0.79% stake in Km Pharmaceutical Co., Ltd. for KRW 400 million.
CI
2014 SV-Growth Ladder Gap Coverage Fund, a fund of SV Investment Corp. acquired 5.93% stake in Km Pharmaceutical Co., Ltd. from Kang, Il-Mo and Moon, Sunggeun for KRW 3 billion.
CI
Seo Seunghee acquired 0.2% stake in Km Pharmaceutical Co., Ltd. from Il-Mo Kang for KRW 100 million.
CI
Youngchan Min acquired 0.49% stake in Km Pharmaceutical Co., Ltd from Il-Mo Kang for KRW 250 million.
CI
Youngchan Min acquired 1.38% stake in Km Pharmaceutical Co., Ltd from Il-Mo Kang for KRW 700 million.
CI
Youngchan Min acquired 0.99% stake in Km Pharmaceutical Co., Ltd from Il-Mo Kang for KRW 500 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A225430 Stock
  4. News KMPHARMACEUTICAL Co.,Ltd.
  5. Highlights